Finnish drug developer Orion's Q2 sales rise, lifts FY outlook
Finnish drug developer Orion's Q2 sales rise, lifts FY outlook
Overview
Finland pharma group's Q2 net sales rose 25% yr/yr, driven by Innovative Medicines and Branded Products
Q2 operating profit up 69%, supported by higher Nubeqa royalty income
Company raised lower end of 2026 net sales and operating profit outlook ranges
Outlook
Orion raises 2026 net sales outlook to EUR 2,000 mln–2,100 mln from EUR 1,950 mln–2,100 mln
Company lifts 2026 operating profit forecast to EUR 650 mln–750 mln from EUR 600 mln–750 mln
Result Drivers
INNOVATIVE MEDICINES - Main growth driver for Q2 net sales
NUBEQA ROYALTIES - Higher Nubeqa royalty income supported improved profitability
R&D EXPENSES - Increased due to expansion and progress of pipeline projects
Company press release: ID:nGNEbSmlg4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| EUR 521.60 mln |
|
Q2 Net Income |
| EUR 140.20 mln |
|
Q2 Basic EPS |
| EUR 1 |
|
Q2 Operating Profit |
| EUR 176.60 mln |
|
Q2 Pretax Profit |
| EUR 175.80 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Orion Oyj is €78.00, about 13.5% above its July 16 closing price of €68.75
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 18 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)